1 P.A. Herzen MCRI (branch of FSBI «NMRRC» of the Ministry of Health of the Russian Federation), Moscow, Russia 2 FSAEI of HPE «PFUR», Moscow, RussiaРезюме Приведены результаты клинического исследования эффективности фотодинамической терапии (ФДТ) с препаратом радахлорин у пациенток с предопухолевой и опухолевой патологией шейки матки. В исследование включено 30 пациенток, в том числе с эрозией шейки матки -4 пациентки, с дисплазией II ст. -5 пациенток, с дисплазией III ст. -13 пациенток, с carcinoma in situ -4 пациентки и с диагнозом рак шейки матки Ia ст. -4 пациентки. Радахлорин вводили однократно внутривенно посредством 30-минутной инфузии в дозе 1,0 мг/кг массы тела за 3 ч до проведения облучения (длина волны 662 нм, плотность энергии 300-350 Дж/см 2 ). Результат лечения у 26 (86,7%) пациенток оценен, как полная регрессия опухоли, у 4 (13,3%) -как частичная регрессия. В группах с клиническим диагнозом эрозия шейки матки, дисплазия II ст. и carcinoma in situ полная регрессия отмечена во всех наблюдениях. В группах с дисплазией III ст. полная регрессия после первого курса ФДТ достигнута у 77% пациенток, с диагнозом рак шейки матки Ia ст. -у 75% больных. У всех больных с частичной регрессией был проведен второй курс ФДТ в срок от 3 до 6 мес после первого курса, после чего была зарегистрирована полная регрессия. В процессе лечения и при последующем наблюдении не было зарегистрировано каких-либо нежелательных реакций, связанных с применением радахлорина или проведением ФДТ. Таким образом, ФДТ с отечественным фотосенсибилизатором радахлорин показала высокую эффективность в лечении предопухолевой и опухолевой патологии шейки матки. Ключевые слова: рак шейки матки, фотосенсибилизатор радахлорин, фотодинамическая терапия. Для цитирования: Филоненко Е.В., Серова Л.Г., Иванова-Радкевич В.И. Результаты III фазы клинических исследований препарата радахлорин для фотодинамической терапии предрака и начального рака райки матки // Biomedical photonics. -2015. -№ 3. -С. 36-42.Контакты: Филоненко Е.В., AbstractThe results of clinical study for efficacy of photodynamic therapy (PDT) with radachlorine in patients with pre-cancer and cancer of cervix are represented. The study enrolled 30 patients including 4 patients with cervical erosion, 5 patients with cervical intraepithelial neoplasia II, 13 patients with cervical intraepithelial neoplasia III, 4 patients with carcinoma in situ and 4 patients with cervical cancer stage Ia. Radachlorine was administrated as single 30 minute intravenous injection at dose of 1,0 mg/kg of body weight 3 h before irradiation (wavelength of 662 nm, light dose of 300-350 J/cm 2 ). The results of treatment in 26 (86,7%) patients was assessed as complete tumor regression and in 4 (13,3%) patients -as partial regression. In cervical erosion, intraepithelial neoplasia II and carcinoma in situ groups total regression was in all cases. In the cervical intraepithelial neoplasia III group total regression after first course of PDT was achieved in 77% of patients, in cervical cancer stage Ia group -in 75% o...
Purpose: To justify the expansion of indications for radiation or chemoradiation therapy in patients with primary or recurrent cervical cancer complicated by hydronephrosis by eliminating obstruction of the ureters. Material and methods: The study included 24 patients who received radiation or chemoradiotherapy from 2012 to 2018. 17 patients among them had primary cervical cancer and the other 7 had a relapse of cervical cancer in small pelvis. In accordance with FIGO and TNM classification (2009), stage IIIB was diagnosed (cT3bN0–1M0) in 16 patients and stage IVB (cT3bN1M1, metastasis in para-aortic lymph nodes) in 1 patient. Prior to the start of special treatment, in all patients was detected one- or two-sided hydronephrosis associated with a neoplastic process and accompanied by varying degrees of impaired parenchymal-excretory function of one of the kidneys. Results: 11 patients underwent unilateral, 3 patients had bilateral ureteral stenting, nephrostomy was superimposed on 9 patients and 1 woman had an ureteral stent installed on one side, nephrostomy on the other side. In 70.8 % (17) patients, the irradiation course was performed without interruption. From 5 to 3 weeks (due to cystitis, endometritis, anemia). In 2 patients, it was not possible to complete the full course of radiotherapy because of the uncoupled effects of pyelonephritis, they were operated on. In the observation period up to 77 months (average observation time 29 months) 16 patients are alive, 12 of them are without signs of disease recurrence. In 6 patients, the natural passage of urine was restored. In 4 patients, the nephrostomy was replaced with a ureteral stent. In 3 patients with ureteral stents they are replaced. Three patients remain with nephrostomy. Eight women died from the progression of the underlying disease, of these, 6 patients with recurrent cervical cancer in the pelvis. Note that in all 6 patients, as a result of the irradiation, a pronounced palliative effect was achieved in the form of relief of pain and bleeding. Conclusion: Performing adequate drainage of the ureter / s allows to expand the indications for radiotherapy or chemoradiation therapy under the radical program in patients with primary or recurrent cervical cancer.
The review considers rare peritoneal tumors that include pseudomyxoma and mesothelioma. Peritoneal pseudomyxoma and mesothelioma are a group of intra-abdominal tumors characterized by a poor prognosis. The literature on the etiology, pathogenesis, and morphological classification of pseudomyxoma and mesothelioma is analyzed. The data from a number of Russian and foreign clinical studies demonstrating different treatment options and their results are given.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.